SCOPUS 정보 검색 플랫폼

OncoImmunology

Volumn 3, Issue 10, 2014, Pages e958949-1-e958949-3

Overcoming immunosuppression to enhance a p53MVA vaccine

(5) Hardwick, Nicola a Chung, Vincent b Cristea, Mihaela b Ellenhorn, Joshua D I c Diamond, Don J a

a Division of Translational Vaccine Research Beckman Research Institute (United States)

b CITY OF HOPE NATIONAL MEDICAL CENTER (United States)

c CEDARS SINAI MEDICAL CENTER (United States)

Author keywords

clinical trial; gemcitabine; immunotherapy; MVA; ovarian cancer; p53

Indexed keywords

CYCLOPHOSPHAMIDE; GEMCITABINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PROGRAMMED DEATH 1 LIGAND 1;

ARTICLE; CANCER CHEMOTHERAPY; DENDRITIC CELL; GASTROINTESTINAL CARCINOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84938631379 PISSN: 21624011 EISSN: 2162402X Source Type: Journal
DOI: 10.4161/21624011.2014.958949 Document Type: Article

Times cited : (11)

References (10)

1
- 84928965963
- p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specfic CD8+ T cell responses
- 24987057
- N.R.Hardwick, M.Carroll, T.Kaltcheva, D.Qian, D.Lim, L.Leong, P.Chu, J.Kim, J.Chao, M.Fakih, p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specfic CD8+ T cell responses. Clin Cancer Res 2014; 20(17):1-12; PMID:24987057; http://dx.doi.org/10.1158/1078-0432.CCR-13-3361
- (2014) Clin Cancer Res , vol.20 , Issue.17 , pp. 1-12
- Hardwick, N.R.¹ Carroll, M.² Kaltcheva, T.³ Qian, D.⁴ Lim, D.⁵ Leong, L.⁶ Chu, P.⁷ Kim, J.⁸ Chao, J.⁹ Fakih, M.¹⁰

2
- 70249141312
- Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial
- 19621448
- N.Leffers, A.J.Lambeck, M.J.Gooden, B.N.Hoogeboom, R.Wolf, I.E.Hamming, B.G.Hepkema, P.H.Willemse, B.H.Molmans, H.Hollema, Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009; 125:2104-13; PMID:19621448; http://dx.doi.org/10.1002/ijc.24597
- (2009) Int J Cancer , vol.125 , pp. 2104-2113
- Leffers, N.¹ Lambeck, A.J.² Gooden, M.J.³ Hoogeboom, B.N.⁴ Wolf, R.⁵ Hamming, I.E.⁶ Hepkema, B.G.⁷ Willemse, P.H.⁸ Molmans, B.H.⁹ Hollema, H.¹⁰

3
- 84859158384
- Targeting the PD-1B7-H1(PD-L1) pathway to activate anti-tumor immunity
- 22236695
- S.L.Topalian, C.G.Drake, D.M.Pardoll. Targeting the PD-1B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
- (2012) Curr Opin Immunol , vol.24 , pp. 207-212
- Topalian, S.L.¹ Drake, C.G.² Pardoll, D.M.³

4
- 78149425157
- Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor
- 20976171
- V.Tjomsland, A.Spangeus, P.Sandstrom, K.Borch, D.Messmer, M.Larsson. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS One 2010; 5:e13441; PMID:20976171; http://dx.doi.org/10.1371/journal.pone.0013441
- (2010) PLoS One , vol.5 , pp. 13441
- Tjomsland, V.¹ Spangeus, A.² Sandstrom, P.³ Borch, K.⁴ Messmer, D.⁵ Larsson, M.⁶

5
- 84863195770
- Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study
- R.Vermeij, N.Leffers, B.N.Hoogeboom, I.L.Hamming, R.Wolf, A.K.Reyners, Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer 2012; 131:E670-80
- (2012) Int J Cancer , vol.131 , pp. 670-680
- Vermeij, R.¹ Leffers, N.² Hoogeboom, B.N.³ Hamming, I.L.⁴ Wolf, R.⁵ Reyners, A.K.⁶

6
- 84896697749
- Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer
- 23860726
- Y.Homma, K.Taniguchi, M.Nakazawa, R.Matsuyama, R.Mori, K.Takeda, Y.Ichikawa, K.Tanaka, I.Endo. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clin Transl Oncol 2014; 16:330-5; PMID:23860726; http://dx.doi.org/10.1007/s12094-013-1079-0
- (2014) Clin Transl Oncol , vol.16 , pp. 330-335
- Homma, Y.¹ Taniguchi, K.² Nakazawa, M.³ Matsuyama, R.⁴ Mori, R.⁵ Takeda, K.⁶ Ichikawa, Y.⁷ Tanaka, K.⁸ Endo, I.⁹

7
- 70849115361
- Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c +dendritic cells in patients with advanced pancreatic cancer
- 19797418
- A.Soeda, Y.Morita-Hoshi, H.Makiyama, C.Morizane, H.Ueno, M.Ikeda, T.Okusaka, S.Yamagata, N.Takahashi, I.Hyodo, Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c +dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2009; 39:797-806; PMID:19797418; http://dx.doi.org/10.1093/jjco/hyp112
- (2009) Jpn J Clin Oncol , vol.39 , pp. 797-806
- Soeda, A.¹ Morita-Hoshi, Y.² Makiyama, H.³ Morizane, C.⁴ Ueno, H.⁵ Ikeda, M.⁶ Okusaka, T.⁷ Yamagata, S.⁸ Takahashi, N.⁹ Hyodo, I.¹⁰

8
- 65549091429
- A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer
- 19276867
- Y.Hirooka, A.Itoh, H.Kawashima, K.Hara, K.Nonogaki, T.Kasugai, E.Ohno, T.Ishikawa, H.Matsubara, M.Ishigami, Y.Katano, N.Ohmiya, Y.Niwa, K.Yamamoto, A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas 2009; 38:e69-74; PMID:19276867; http://dx.doi.org/10.1097/MPA.0b013e318197a9e3
- (2009) Pancreas , vol.38 , pp. 69-74
- Hirooka, Y.¹ Itoh, A.² Kawashima, H.³ Hara, K.⁴ Nonogaki, K.⁵ Kasugai, T.⁶ Ohno, E.⁷ Ishikawa, T.⁸ Matsubara, H.⁹ Ishigami, M.¹⁰ Katano, Y.¹¹ Ohmiya, N.¹² Niwa, Y.¹³ Yamamoto, K.¹⁴

9
- 78650667121
- Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer
- 21150717
- M.Kaida, Y.Morita-Hoshi, A.Soeda, T.Wakeda, Y.Yamaki, Y.Kojima, H.Ueno, S.Kondo, C.Morizane, M.Ikeda, Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 2011; 34:92-9; PMID:21150717; http://dx.doi.org/10.1097/CJI.0b013e3181fb65b9
- (2011) J Immunother , vol.34 , pp. 92-99
- Kaida, M.¹ Morita-Hoshi, Y.² Soeda, A.³ Wakeda, T.⁴ Yamaki, Y.⁵ Kojima, Y.⁶ Ueno, H.⁷ Kondo, S.⁸ Morizane, C.⁹ Ikeda, M.¹⁰

10
- 4644237613
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
- 15322536
- T.J.Curiel, G.Coukos, L.Zou, X.Alvarez, P.Cheng, P.Mottram, M.Evdemon-Hogan, J.R.Conejo-Garcia, L.Zhang, M.Burow, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
- (2004) Nat Med , vol.10 , pp. 942-949
- Curiel, T.J.¹ Coukos, G.² Zou, L.³ Alvarez, X.⁴ Cheng, P.⁵ Mottram, P.⁶ Evdemon-Hogan, M.⁷ Conejo-Garcia, J.R.⁸ Zhang, L.⁹ Burow, M.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.